Readmission Risk Factors and Heart Failure With Preserved Ejection Fraction

Heart Failure Clinical Trial

Official title:

Readmission Risk Factors and Heart Failure With Preserved Ejection Fraction

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04008914
• Other study ID #: AscensionMacombOaklandH
• Status: Completed
• Start date: August 1, 2017
• Est. completion date: January 18, 2019

Study information

• Verified date: July 2019
• Source: Ascension Macomb-Oakland Hospital
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

Retrospective review of 492 patient from a small community hospital who did not qualify for participation in the Connect HF study sponsored by DCRI.

Description:

Retrospective review of adults above the age of 18 with a primary diagnosis of HFpEF between August 2017 and March 2018. Subjects had to fall into one of two classifications (NYHA Class II-IV or ACC/AHA Stage B-D) and had a life expectancy greater than 6 months are included. Individuals with a terminal illness other than HF, prior heart transplant or on a transplant list, or current/ planned left ventricular assist device excluded. The primary objective of this study is to identify risk factors for readmission in patients discharged with a diagnosis of HFpEF.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 492
• Est. completion date: January 18, 2019
• Est. primary completion date: March 1, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• History of Heart failure diagnosis admitted for treatment

• Ejection fraction < 40% by echocardiogram

Exclusion Criteria:

• Ejection fraction >40% by echocardiogram

• Chronic Kidney disease requiring dialysis

• Terminal illness

• New onset diagnosis of Heart Failure

Related Conditions & MeSH terms

• Heart Failure
• Preserved Ejection Fraction

Intervention

Other:
• retrospective observation
Retrospective review of study patients excluded from the CONNECT- HF trial who were discharged with a diagnosis of HFpEF between August 1, 2017 and March 1, 2018. Readmission rate at 30 and 90 days along with patient demographics and associated comorbidities were analyzed.

Locations

Country	Name	City	State
United States	Ascension Macomb-Oakland Hospital	Warren	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
Ascension Macomb-Oakland Hospital

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Readmission Risk Factors and Heart Failure with Preserved Ejection Fraction	Retrospective review to identify risk factors for readmission in patients discharged with a diagnosis of HFpEF.	August 1, 2017 though March 1, 2018